Top

World Journal of Urology

Published in:

01-01-2018 | Letter to the Editor

AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?

Authors: Igor Tsaur, Hendrik Borgmann, Christian I. Surcel, Piet Ost, Guillaume Ploussard

Published in: World Journal of Urology | Issue 1/2018

Excerpt

Dear Editor, …

Taplin M-E, Antonarakis ES, Ferrante KJ, Horgan K, Blumenstein BA, Saad F, Luo J, De Bono JS (2017) Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7 + metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 35:(suppl; abstr 5005)

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028–1038CrossRefPubMedPubMedCentral

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2015) Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 1:582–591CrossRefPubMedPubMedCentral

Bernemann C, Schnoeller TJ, Luedeke M, Steinestel K, Boegemann M, Schrader AJ, Steinestel J (2017) Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer. Eur Urol 71:1–3CrossRefPubMed

Qu F, Xie W, Nakabayashi M, Zhang H, Jeong SH, Wang X, Komura K, Sweeney CJ, Sartor O, Lee GM, Kantoff PW (2017) Association of AR-V7 and prostate-specific antigen rna levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. Clin Cancer Res 23:726–734CrossRefPubMed

Scher HI, Graf RP, Schreiber NA, McLaughlin B, Lu D, Louw J, Danila DC, Dugan L, Johnson A, Heller G, Fleisher M, Dittamore R (2017) Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer. Eur Urol 71:874–882CrossRefPubMed

Title: AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?
Authors: Igor Tsaur
Hendrik Borgmann
Christian I. Surcel
Piet Ost
Guillaume Ploussard
Publication date: 01-01-2018
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 1/2018
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-017-2107-4

At a glance: The STEP trials

Springer Medicine

AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2018

Management of renal transplant urolithiasis: a multicentre study by the French Urology Association Transplantation Committee

Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy

Complications of penile self-injections: investigation of 680 patients with complications following penile self-injections with mineral oil

Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques

Effect of post-nephrectomy acute kidney injury on renal outcome: a retrospective long-term study

Reply to the Letter to the Editor by Reza Pakzad and Saeid Safiri, integration of MRI to clinical nomogram for predicting pathological stage before radical prostatectomy: bias in the prediction model